

1645


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.

15120

In Re Application Of: Joachim Hauber, et al.



Serial No.

10/025,367

Filing Date

December 19, 2001

Examiner

Unassigned

Group Art Unit

1645

Title:

COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
 2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

RECEIVED

MAY 01 2003

TECH CENTER 1600/2900

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

15120

In Re Application Of: Joachim Hauber, et al.

APR 30 2003

Serial No.

10/025,367

Filing Date

December 19, 2001

Examiner

Unassigned

Group Art Unit

1645

Title:

COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____ (Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on April 24, 2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Michelle Mustafa

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Dated: April 24, 2003

RECEIVED

MAY 01 2003

TECH CENTER 1600/2900

Peter I. Bernstein
Registration No. 43,497
SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343

PIB:dg

CC:



IDS/ #9
J 5.2.03

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Joachim Hauber, et al.	Examiner:	Unassigned
Serial No:	10/025,367	Art Unit:	1645
Filed:	December 19, 2001	Docket:	15120
For:	COMPOUNDS THAT AFFECT CD83 EXPRESSION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHODS FOR IDENTIFYING SAID COMPOUNDS	Dated:	April 24, 2003

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. International Patent Publication No. WO 95/21916, dated August 17, 1995;
2. Rebel J.M.J. et al., "Identification of a pp32-Related Locus on Chromosome 12", *EMBL Genbank #HSU71084* (1997), XP002106402;
3. Ross R.A. et al., "HuD, a Neuronal-Specific RNA-Binding Protein, is a Potential Regulator of MYCN Expression in Human Neuroblastoma Cells", *European Journal of Cancer* 33(12): 2071-2074 (1997);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on April 24, 2003.

Dated: April 24, 2003



Michelle Mustafa

4. Chung S. et al., "The Elav-like Proteins Bind to a Conserved Regulatory Element in the 3'-Untranslated Region of GAP-43 mRNA*", *The Journal of Biological Chemistry* 272(10):6593-6598 (1997), XP002920798;
5. International Patent Publication No. WO 99/12965, dated March 18, 1999; and
6. Brennan C.M. et al., "Protein Ligands to HuR Modulate Its Interaction with Target mRNAs In Vivo", *The Journal of Cell Biology* 151(1):1-13 (2000), XP002230286.

The references were cited in a Search Report received from the European Patent Office, dated February 27, 2003. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Peter I. Bernstein

Registration No.: 43,497

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

PIB:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT <div style="border: 1px solid black; border-radius: 50%; padding: 10px; width: 100px; float: left; margin-right: 10px;"> OFFICE APR 30 2003 PATENT & TRADEMARK OFFICE </div> <i>(Use several sheets if necessary)</i>		Atty. Docket No. (Optional) 15120	Application Number 10/025,367				
Applicant(s) Joachim Hauber, et al.		Filing Date December 19, 2001					
Group Art Unit 1645							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
		WO 95/21916	8/17/95	PCT			RECEIVED MAY 01 2003 TECH CENTER 1600/2900
		WO 99/12965	3/18/99	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Rebel J.M.J. et al., "Identification of a pp32-Related Locus on Chromosome 12", <i>EMBL Genbank</i> #HSU71084 (1997), XP002106402					
		Ross R.A. et al., "HuD, a Neuronal-Specific RNA-Binding Protein, is a Potential Regulator of MYCN Expression in Human Neuroblastoma Cells", <i>European Journal of Cancer</i> 33(12): 2071-2074 (1997)					
		Chung S. et al., "The Elav-like Proteins Bind to a Conserved Regulatory Element in the 3'-Untranslated Region of GAP-43 mRNA*", <i>The Journal of Biological Chemistry</i> 272(10):6593-6598 (1997), XP002920798					
		Brennan C.M. et al., "Protein Ligands to HuR Modulate Its Interaction with Target mRNAs In Vivo", <i>The Journal of Cell Biology</i> 151(1):1-13 (2000), XP002230286					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							